Fentanyl Polysubstance Use Patterns and Their Associations With Hepatitis C Virus, Skin and Soft Tissue Infections, and Non-Fatal Overdose Among People Who Inject Drugs in New York City.

INTRODUCTION

Fentanyl's euphoric effects and short half-life may increase infectious disease transmission risks through frequent injecting and syringe sharing. We examined fentanyl polysubstance use (PSU) patterns and associations with hepatitis C virus (HCV), skin and soft tissue infections (SSTI), and non-fatal overdose among people who inject drugs (PWID) in New York City.

METHODS

We recruited 495 PWID between October 2021 and July 2024. Participants were tested for HCV antibody and underwent urine toxicology screenings using the Premier Biotech 13-panel BioCup.

RESULTS

Fentanyl was identified in 83.6% of the sample; however, only 23.0% self-reported recent intentional fentanyl use. The most common fentanyl PSU combinations were fentanyl with methadone (67.9%), opiates (66.9%), cocaine (65.9%), cannabis (45.4%), xylazine (36.7%), heroin (35.5%), benzodiazepines (32.5%) and alcohol (29.3%). Compared to no fentanyl use, intentional fentanyl use was associated with HCV antibody seropositivity (aOR 3.44, 95% CI 1.75, 6.93), SSTIs (aOR 4.75, 1.66, 17.20) and non-fatal overdose (aOR 2.35, 1.15, 5.00). Co-use of fentanyl with opiates (aOR 2.08, 1.16, 3.82), cocaine (aOR 2.71, 1.52, 4.97), heroin (aOR 2.06, 1.11, 3.91), benzodiazepines (aOR 2.91, 1.55, 5.63) and alcohol (aOR 3.27, 1.72, 6.37) were associated with HCV. Co-use of fentanyl with benzodiazepines (aOR 2.08, 1.04, 4.34) and alcohol (aOR 2.57, 1.29, 5.37) were associated with non-fatal overdose.

DISCUSSION AND

CONCLUSIONS

In addition to overdose, when combined with other psychoactive substances, fentanyl PSU is associated with a higher prevalence of infectious diseases. This underscores the need for tailored medication dosing for opioid use disorder and expanding access to syringe service programs and medical care for PWID in the fentanyl era.